Article

A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals.

Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 61 President Street, Charleston, SC 29425, USA.
American Journal on Addictions (impact factor: 1.74). 13(1):53-63. pp.53-63
Source: PubMed

ABSTRACT Anxiety symptoms are common among opioid-dependent individuals. Buspirone, a nonbenzodiazepine anxiolytic, has been used successfully for the treatment of anxiety in alcoholic patients. Its efficacy in opioid-dependent patients has not been previously examined. We conducted a twelve-week, randomized, placebo-controlled trial of buspirone in 36 subjects receiving methadone-maintenance treatment who presented with anxiety symptoms. Measures of anxiety, depression, and substance use were obtained repeatedly during treatment. Buspirone treatment did not significantly reduce anxiety symptoms in opioid-dependent patients. However, buspirone treatment was associated with trends toward reduction in depression scale scores and a slower return to substance use.

0 0
 · 
0 Bookmarks
 · 
22 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

36 subjects
 
alcoholic patients
 
anxiety symptoms
 
Buspirone
 
buspirone treatment
 
depression scale scores
 
efficacy
 
Measures
 
methadone-maintenance treatment
 
opioid-dependent patients
 
placebo-controlled trial
 
slower return
 
substance use
 
trends
 
twelve-week